Infusion-Related Reactions With Pegloticase, a Recombinant Uricase for the Treatment of Chronic Gout Refractory to Conventional Therapy
Open Access
- 1 December 2014
- journal article
- review article
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 20 (8) , 427-432
Abstract
In clinical trials of pegloticase, a PEGylated uricase developed for treatment of gout refractory to conventional therapy, infusion-related reactions (IRs) were the second most frequent adverse event reported. The objective of this study was to provide a detailed account of IRs with pegloticase therapy. Data from 2 replicate, 6-month randomized trials and an open-label extension study were pooled. Infusions of pegloticase (8 mg) were administered biweekly or monthly; all patients received prophylaxis (antihistamine, acetaminophen, and corticosteroid) and were tested for urate levels prior to each infusion. An IR was defined by protocol as any otherwise unexplained adverse event or cluster of temporally related events occurring during or within 2 hours of infusion. Infusion-related reactions occurred in 94 (45%) of 208 patients receiving pegloticase; 10 patients reported IRs at first infusion and 84 during subsequent infusions. Chest discomfort (15%), flushing (12%), and dyspnea (11%) were the most common symptoms. Most IRs were rated mild or moderate; 7% were rated severe. All IRs resolved with slowing, interrupting, or stopping the infusion. No patient required blood pressure or ventilatory support. Infusion-related reactions were associated with loss of pegloticase urate-lowering efficacy: 91% of all IRs occurred in patients with preinfusion serum uric acid concentrations (sUA) greater than 6 mg/dL. For patients sustaining preinfusion sUA of less than 6 mg/dL, IRs occurred in fewer than 1 per 100 infusions. Phase 3 trial data combined with post hoc analyses demonstrated that knowledge of sUA preceding each pegloticase infusion and cessation of therapy when urate-lowering efficacy is lost provide a means to optimize the safety of pegloticase in clinical practice.Keywords
This publication has 8 references indexed in Scilit:
- Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic goutArthritis Research & Therapy, 2014
- Long-term safety of pegloticase in chronic gout refractory to conventional treatmentAnnals of the Rheumatic Diseases, 2013
- Pegloticase and Chronic Gout--ReplyJAMA, 2011
- Efficacy and Tolerability of Pegloticase for the Treatment of Chronic Gout in Patients Refractory to Conventional TreatmentJAMA, 2011
- PegloticaseNature Reviews Drug Discovery, 2010
- Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory goutArthritis & Rheumatism, 2007
- Second Symposium on the Definition and Management of Anaphylaxis: Summary Report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network SymposiumAnnals of Emergency Medicine, 2006
- Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidaseArthritis Research & Therapy, 2005